NCT06676527
Vorolanib in the Second-line Treatment of Patients With Unresectable or Metastatic Renal Cell Carcinoma
At risk: Primary completion moved 6 months later.
Track this trial
Free. We email you which fields changed when ClinicalTrials.gov updates this record.
Record History
All 3 versions: 3 with changes below. See every version on ClinicalTrials.gov ↗
- Notable Primary completion pushed from Sep 1, 2026 to Mar 1, 2027
- Eligibility criteria expanded, about 21 words
- Study completion pushed from Sep 1, 2026 to Mar 1, 2028
- Study Identification, Study Status, Oversightv2
- Study First Submitted
- Notable: the plan changed
Endpoints
Primary
Progression Free Survival (PFS)
Timeframe: From enrollment to the end of treatment at 12 weeks.
Treatment Related Adverse Events (TRAEs)
Timeframe: From enrollment to up to 90 days after treatment at 12 weeks or reported.
Secondary (3)
Overall Survival (OS)
Objective Response Rate (ORR)
Disease Control Rate (DCR)
Arms and interventions
Experimental cohort.
Subjects who progressed after first-line treatment and switched to second-line treatment regimens including vorolanib. The first-line treatment which patients received can be other tyrosine kinase inhibitors (TKIs) or TKIs combined with immunotherapy drugs. Provided vorolanib is contained in the second-line regimen, the patient then can be considered for inclusion in the study.
Other: Follow-up study of the treated cohort
Sites
1 site in 1 country
- Jinling HospitalNanjing, Jiangsu, China